ArticleBMJ open2022

Rationale and design of a multicentre, 12-week, randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated trial to investigate the efficacy and safety of elobixibat for chronic constipation.

Kosuke Tanaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.